Head-to-head · WeighScore
NuuVim vs This Gen Wellness
The verdict
NuuVim takes it — 68.2/100 to 56.9/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuuVim | This Gen Wellness |
|---|---|---|
| WeighScore | 68.2/100 | 56.9/100 |
| Grade | C | C |
| Scorecard rank | #153 | #405 |
| Semaglutide | $79/mo (all doses, 3-mo plan, new patients only, compounded) | Not disclosed |
| Tirzepatide | $133/mo (all doses, 3-mo plan, new patients only, compounded) | Not disclosed |
| Coverage | Coverage not published | 1 state |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #153 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Graded #405 · C
Strengths
- Requires a synchronous live audio-video visit with a New York-licensed clinician — prescriptions are never issued from the intake form alone
- Assessment and clinician review are free; you only pay if treatment is prescribed and you choose to proceed
- Names its legal entity (ThisGen, LLC) and specifies New York governing law in its terms
- No long-term contracts — plans can be paused or stopped
- The same clinician follows your care, with ongoing secure messaging between visits
Where it loses points
- Publishes no prices at all — 'We don't list flat prices on the website'; cost is disclosed only after a clinician reviews your assessment
- Serves New York only — 'we currently operate exclusively for patients located in New York'
- Dispensing pharmacies are not named, only described as 'licensed U.S. pharmacies'
- Does not state whether its semaglutide and tirzepatide are compounded or brand-name
- Does not bill insurance; verifying any reimbursement is the patient's responsibility
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.